217 related articles for article (PubMed ID: 21819622)
1. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.
Romero Q; Bendahl PO; Klintman M; Loman N; Ingvar C; Rydén L; Rose C; Grabau D; Borgquist S
BMC Cancer; 2011 Aug; 11():341. PubMed ID: 21819622
[TBL] [Abstract][Full Text] [Related]
2. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
[TBL] [Abstract][Full Text] [Related]
3. Effect of neoadjuvant therapy on breast cancer biomarker profile.
Rey-Vargas L; Mejía-Henao JC; Sanabria-Salas MC; Serrano-Gomez SJ
BMC Cancer; 2020 Jul; 20(1):675. PubMed ID: 32682413
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
Knutsvik G; Stefansson IM; Aziz S; Arnes J; Eide J; Collett K; Akslen LA
PLoS One; 2014; 9(11):e112121. PubMed ID: 25375149
[TBL] [Abstract][Full Text] [Related]
5. Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer.
Tokuda E; Horimoto Y; Arakawa A; Himuro T; Senuma K; Nakai K; Saito M
Hum Pathol; 2017 May; 63():40-45. PubMed ID: 28237784
[TBL] [Abstract][Full Text] [Related]
6. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Robertson S; Rönnlund C; de Boniface J; Hartman J
Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens.
Ahn S; Lee J; Cho MS; Park S; Sung SH
Arch Pathol Lab Med; 2018 Mar; 142(3):364-368. PubMed ID: 29144790
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.
Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
Breast Cancer Res Treat; 2009 Jul; 116(1):53-68. PubMed ID: 18592370
[TBL] [Abstract][Full Text] [Related]
9. Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume.
Focke CM; Decker T; van Diest PJ
Ann Surg Oncol; 2017 May; 24(5):1251-1257. PubMed ID: 28008571
[TBL] [Abstract][Full Text] [Related]
10. A simple digital image analysis system for automated Ki67 assessment in primary breast cancer.
Alataki A; Zabaglo L; Tovey H; Dodson A; Dowsett M
Histopathology; 2021 Aug; 79(2):200-209. PubMed ID: 33590538
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.
Iwamoto T; Katagiri T; Niikura N; Miyoshi Y; Kochi M; Nogami T; Shien T; Motoki T; Taira N; Omori M; Tokuda Y; Fujiwara T; Doihara H; Gyorffy B; Matsuoka J
Oncotarget; 2017 Apr; 8(16):26122-26128. PubMed ID: 28412725
[TBL] [Abstract][Full Text] [Related]
12. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
Acs B; Leung SCY; Kidwell KM; Arun I; Augulis R; Badve SS; Bai Y; Bane AL; Bartlett JMS; Bayani J; Bigras G; Blank A; Buikema H; Chang MC; Dietz RL; Dodson A; Fineberg S; Focke CM; Gao D; Gown AM; Gutierrez C; Hartman J; Kos Z; Lænkholm AV; Laurinavicius A; Levenson RM; Mahboubi-Ardakani R; Mastropasqua MG; Nofech-Mozes S; Osborne CK; Penault-Llorca FM; Piper T; Quintayo MA; Rau TT; Reinhard S; Robertson S; Salgado R; Sugie T; van der Vegt B; Viale G; Zabaglo LA; Hayes DF; Dowsett M; Nielsen TO; Rimm DL;
Mod Pathol; 2022 Oct; 35(10):1362-1369. PubMed ID: 35729220
[TBL] [Abstract][Full Text] [Related]
13. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
14. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
[TBL] [Abstract][Full Text] [Related]
15. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H
Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496
[TBL] [Abstract][Full Text] [Related]
17. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
Martin LA; Davies GL; Weigel MT; Betambeau N; Hills MJ; Salter J; Walsh G; A'Hern R; Dowsett M
Breast Cancer Res Treat; 2010 Oct; 123(3):829-36. PubMed ID: 20697803
[TBL] [Abstract][Full Text] [Related]
18. A novel model for Ki67 assessment in breast cancer.
Romero Q; Bendahl PO; Fernö M; Grabau D; Borgquist S
Diagn Pathol; 2014 Jun; 9():118. PubMed ID: 24934660
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy with celecoxib to women with early stage breast cancer.
Tfayli A; Yang J; Kojouri K; Kesserwan C; Jafari M; Ozer H
Neoplasma; 2008; 55(2):122-6. PubMed ID: 18237249
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
